ATE373084T1 - Verfahren zur herstellung von gereinigtem hcv rna durch isolierung von exosomen - Google Patents

Verfahren zur herstellung von gereinigtem hcv rna durch isolierung von exosomen

Info

Publication number
ATE373084T1
ATE373084T1 AT00979837T AT00979837T ATE373084T1 AT E373084 T1 ATE373084 T1 AT E373084T1 AT 00979837 T AT00979837 T AT 00979837T AT 00979837 T AT00979837 T AT 00979837T AT E373084 T1 ATE373084 T1 AT E373084T1
Authority
AT
Austria
Prior art keywords
isolation
exosomes
hcv rna
producing purified
purified hcv
Prior art date
Application number
AT00979837T
Other languages
German (de)
English (en)
Inventor
Sergio Abrignani
Piero Pileri
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE373084T1 publication Critical patent/ATE373084T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00979837T 1999-11-18 2000-11-20 Verfahren zur herstellung von gereinigtem hcv rna durch isolierung von exosomen ATE373084T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9927320.3A GB9927320D0 (en) 1999-11-18 1999-11-18 Exosome separation

Publications (1)

Publication Number Publication Date
ATE373084T1 true ATE373084T1 (de) 2007-09-15

Family

ID=10864765

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00979837T ATE373084T1 (de) 1999-11-18 2000-11-20 Verfahren zur herstellung von gereinigtem hcv rna durch isolierung von exosomen

Country Status (13)

Country Link
US (2) US7198923B1 (enExample)
EP (1) EP1230347B1 (enExample)
JP (1) JP4675017B2 (enExample)
AT (1) ATE373084T1 (enExample)
AU (1) AU1721801A (enExample)
CA (1) CA2392075C (enExample)
CY (1) CY1107521T1 (enExample)
DE (1) DE60036403T2 (enExample)
DK (1) DK1230347T3 (enExample)
ES (1) ES2292489T3 (enExample)
GB (1) GB9927320D0 (enExample)
PT (1) PT1230347E (enExample)
WO (1) WO2001036601A1 (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9927320D0 (en) * 1999-11-18 2000-01-12 Chiron Spa Exosome separation
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
WO2005121369A2 (en) * 2004-06-02 2005-12-22 Sourcepharm, Inc. Rna-containing microvesicles and methods therefor
EP3517151B1 (en) * 2006-03-09 2021-04-21 Aethlon Medical, Inc. Extracorporeal removal of microvesicular particles
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
ES2936256T3 (es) 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas
US11266736B2 (en) 2008-04-17 2022-03-08 Vin De Bona Trading Company Pte Ltd Method of painting micro vesicles
WO2009155505A2 (en) * 2008-06-20 2009-12-23 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
US9487837B2 (en) * 2008-10-06 2016-11-08 Morehouse School Of Medicine Exosome-mediated diagnosis of hepatitis virus infections and diseases
US10545149B2 (en) * 2008-10-06 2020-01-28 Morehouse School Of Medicine Detection of HIV-related proteins in urine
EP2358912B1 (en) 2008-10-30 2016-10-12 Caris Life Sciences Switzerland Holdings GmbH Methods for assessing rna patterns
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
US20130053426A1 (en) * 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
BRPI0900815A2 (pt) * 2009-04-23 2010-12-28 Sociedade Benef Israelita Bras Hospital Albert Einstein método para isolamento de exossomos a partir de soluções biológicas utilizando nanopartìculas de óxido de ferro
SG177677A1 (en) 2009-07-16 2012-02-28 Gen Hospital Corp Nucleic acid analysis
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
WO2011031892A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
JPWO2011049059A1 (ja) * 2009-10-22 2013-03-14 国立大学法人岐阜大学 Ｒｎａ内包キャリア組成物
EP2507393A4 (en) 2009-11-30 2013-05-01 Caris Life Sciences Luxembourg Holdings METHODS AND SYSTEMS FOR ISOLATING, STORING AND ANALYZING VESICLES
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
WO2011156734A2 (en) * 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Method of characterizing vascular diseases
WO2011156763A1 (en) 2010-06-11 2011-12-15 Hitachi Chemical Co., Ltd. Methods for characterizing kidney function
EP2591359B1 (en) 2010-07-07 2017-03-01 Aethlon Medical Inc Methods for quantifying exosomes
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2638057B1 (en) 2010-11-10 2019-03-06 Exosome Diagnostics, Inc. Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom
ES2744589T3 (es) 2011-05-11 2020-02-25 Exosome Diagnostics Inc Extracción de ácido nucleico de materiales biológicos heterogéneos
JP5823031B2 (ja) 2011-06-10 2015-11-25 日立化成株式会社 小胞捕捉デバイスおよびそれを用いるための方法
EP2723865B1 (en) 2011-06-21 2019-03-27 Alnylam Pharmaceuticals, Inc. METHODS FOR DETERMINING ACTIVITY OF RNAi IN A SUBJECT
EP3492606B1 (en) 2011-08-22 2023-10-04 Exosome Diagnostics, Inc. Urine biomarkers
EP2758774A4 (en) * 2011-09-22 2015-04-29 Univ Los Andes METHOD FOR MONITORING, DIAGNOSIS AND / OR FORECASTING ACUTE CHILDIER INJURY IN AN EARLY STAGE
EP2776587A4 (en) 2011-11-10 2015-07-15 Exosome Diagnostics Inc LIQUOR ASSAY
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2014012168A1 (en) * 2012-07-19 2014-01-23 Anirban Ghosh Method for the isolation of microvesicles
CN104995311A (zh) 2012-08-30 2015-10-21 外来体诊断公司 用于核酸测定的对照
CA2887058C (en) 2012-10-03 2022-02-22 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
DK2906717T3 (en) 2012-10-11 2019-04-01 Vin De Bona Trading Company Pte Ltd PROCEDURE FOR PAINTING MICROVESICS
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
MX392552B (es) 2013-01-03 2025-03-11 Exosome Diagnostics Inc Métodos para aislar microvesículas.
WO2014159662A1 (en) 2013-03-13 2014-10-02 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
JP6297676B2 (ja) 2013-05-06 2018-03-20 日立化成株式会社 標的分子を捕捉するためのデバイス及び方法
CN106029900B (zh) 2013-08-06 2020-02-28 外来体诊断公司 尿生物标志物群、基因表达特征及其使用方法
CN105980615A (zh) 2013-08-28 2016-09-28 卡里斯生命科学瑞士控股有限公司 寡核苷酸探针及其用途
US9958460B2 (en) * 2013-10-24 2018-05-01 Nanosomix, Inc. Biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders
WO2015112382A1 (en) * 2014-01-21 2015-07-30 Morehouse School Of Medicine Exosome-mediated detection of infections and diseases
WO2015153732A2 (en) 2014-04-01 2015-10-08 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
US11268085B2 (en) 2014-05-27 2022-03-08 Exosome Diagnostics, Inc. Methods for isolating microvesicles and extracting nucleic acids from biological samples
US10465183B2 (en) 2014-07-09 2019-11-05 Exosome Diagnostics, Inc. Methods for isolating microvesicles and extracting nucleic acids from biological samples
WO2016011383A1 (en) 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Methods for using exosomes to monitor transplanted organ status
US10266895B2 (en) 2014-11-05 2019-04-23 Hitachi Chemical Company Ltd. Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease
EP3218521B1 (en) 2014-11-12 2019-12-25 Hitachi Chemical Co., Ltd. Method for diagnosing organ injury
EP3112474A1 (en) 2015-06-29 2017-01-04 Evonik Degussa GmbH Method of detecting avian necrotic enteritis
AU2016229076B2 (en) 2015-03-09 2022-01-20 Caris Science, Inc. Oligonucleotide probes and uses thereof
IL256175B2 (en) 2015-06-10 2024-10-01 Univ Texas Using exosomes to treat the disease
IL256634B2 (en) 2015-06-29 2025-08-01 Caris Science Inc Therapeutic oligonucleotides
US10941176B2 (en) 2015-07-28 2021-03-09 Caris Science, Inc. Therapeutic oligonucleotides
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease
EP3165926A1 (en) 2015-11-06 2017-05-10 Humanitas Mirasole S.p.A. Method for characterization of cell specific microvesicles
WO2018057820A1 (en) 2016-09-21 2018-03-29 Predicine, Inc. Systems and methods for combined detection of genetic alterations
US11702702B2 (en) 2016-04-15 2023-07-18 Predicine, Inc. Systems and methods for detecting genetic alterations
US20190093172A1 (en) 2016-04-15 2019-03-28 Exosome Diagnostics, Inc. Plasma-based detection of anaplastic lymphoma kinase (alk) nucleic acids and alk fusion transcripts and uses thereof in diagnosis and treatment of cancer
MX2018013341A (es) 2016-05-02 2019-09-18 Encodia Inc Analisis de macromoleculas que emplea la codificacion de acido nucleico.
EP3452613B1 (en) 2016-05-05 2021-12-29 Exosome Diagnostics, Inc. Profiling microvesicle nucleic acids and uses thereof as signatures in diagnosis of renal transplant rejection
EP4079853A1 (en) 2016-05-13 2022-10-26 Exosome Diagnostics, Inc. Automated and manual methods for isolation of extracellular vesicles and co-isolation of cell-free dna from biofluids
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
WO2018055080A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
JP2019535307A (ja) 2016-10-21 2019-12-12 エクソサム ダイアグノスティクス，インコーポレイティド エキソソーム結合型核酸の配列決定および分析
EP3548635B1 (en) 2016-11-30 2021-04-28 Exosome Diagnostics, Inc. Methods to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients
GB2559319B (en) 2016-12-23 2019-01-16 Cs Genetics Ltd Reagents and methods for the analysis of linked nucleic acids
WO2018126278A2 (en) 2017-01-02 2018-07-05 Exosome Diagnostics, Inc. Methods to distinguish rna and dna in a combined preparation
HUE062498T2 (hu) 2017-05-12 2023-11-28 Evonik Operations Gmbh Eljárás madárállományban C. perfringens által kiváltott betegségek kimutatására
JP7225121B2 (ja) 2017-05-17 2023-02-20 エクソサム ダイアグノスティクス，インコーポレイティド 微小胞核酸および／またはタンパク質、並びに腎移植拒絶反応マーカーとしてのその使用
US11899024B2 (en) 2017-07-12 2024-02-13 Exosome Diagnostics, Inc. Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles
EP3655531B1 (en) 2017-07-18 2024-09-04 Exosome Diagnostics, Inc. Sequencing of nucleic acids associated with exosomal isolation from patients with glioblastoma multiforme
EP3704249B1 (en) 2017-10-31 2025-05-21 Encodia, Inc. Kits for analysis using nucleic acid encoding and/or label
EP3707278A1 (en) 2017-11-09 2020-09-16 Alnylam Pharmaceuticals Inc. Assays and methods for determining expression of the lect2 gene
CN110123838B (zh) * 2018-02-02 2022-04-01 上海睿泰生物科技股份有限公司 负载白藜芦醇的人多能干细胞外泌体及其制备方法与用途
CN110123841A (zh) * 2018-02-09 2019-08-16 上海市第六人民医院 负载白藜芦醇的人多能干细胞外泌体在制备治疗生殖系统疾病药物的用途
MX2020009044A (es) 2018-03-02 2020-10-12 Evonik Operations Gmbh Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales.
CN112739832B (zh) 2018-06-06 2024-06-04 外来体诊断公司 用于开发尿液生物标志物和用于检测膀胱癌的方法
US12258587B2 (en) 2018-11-20 2025-03-25 Exosome Diagnostics, Inc. Compositions and methods for internal controls of microvesicle isolations
US12449424B2 (en) 2018-12-14 2025-10-21 Evonik Operations Gmbh In vitro method for detecting avian intestinal dysbiosis
CN114072499B (zh) 2019-04-30 2024-08-06 Encodia公司 用于制备分析物的方法和相关试剂盒
WO2021055770A2 (en) * 2019-09-18 2021-03-25 Exosome Diagnostics, Inc. Compositions, methods, and kits for the isolation of extracellular vesicles
AU2021255132A1 (en) 2020-04-13 2022-12-08 Exoprother Medical Ltd. Cell-derived vesicles comprising wild-type P53 protein for antiviral therapy
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
IL277743A (en) 2020-10-01 2022-04-01 Yeda Res & Dev A method for diagnosing breast cancer
TW202214851A (zh) * 2020-10-07 2022-04-16 國立中央大學 外泌體核酸萃取方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225068B1 (en) * 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
AU7672991A (en) * 1990-04-03 1991-10-30 Southwest Foundation For Biomedical Research Purified hcv and hcv proteins and peptides
GB9416671D0 (en) 1994-08-17 1994-10-12 Biocine Spa Assay
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
GB9517926D0 (en) 1995-09-01 1995-11-01 Biocine Spa Binding protein
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
EP1021534B1 (en) * 1997-10-06 2009-11-25 Novartis Vaccines and Diagnostics S.r.l. Hepatitis c receptor protein cd81
CA2305715A1 (en) 1997-11-06 1999-05-20 Innogenetics N.V. Host derived proteins binding hcv: medical, diagnostic and purification use
GB9927320D0 (en) * 1999-11-18 2000-01-12 Chiron Spa Exosome separation

Also Published As

Publication number Publication date
JP2003514523A (ja) 2003-04-22
CA2392075A1 (en) 2001-05-25
US7198923B1 (en) 2007-04-03
JP4675017B2 (ja) 2011-04-20
CY1107521T1 (el) 2013-03-13
US7807438B2 (en) 2010-10-05
WO2001036601A1 (en) 2001-05-25
GB9927320D0 (en) 2000-01-12
EP1230347B1 (en) 2007-09-12
DK1230347T3 (da) 2007-11-05
AU1721801A (en) 2001-05-30
CA2392075C (en) 2011-01-04
DE60036403D1 (de) 2007-10-25
PT1230347E (pt) 2007-12-20
US20070254351A1 (en) 2007-11-01
DE60036403T2 (de) 2008-06-12
ES2292489T3 (es) 2008-03-16
EP1230347A1 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
ATE373084T1 (de) Verfahren zur herstellung von gereinigtem hcv rna durch isolierung von exosomen
DE60142562D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
DE60119968D1 (en) Hepatitis c tripeptid inhibitoren
IS7533A (is) Lifrarbólgu C-veirutálmar
ATE434035T1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
WO2004043339A3 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
DE60142683D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
AU2002360592A1 (en) Inhibitors of hepatitis c virus
DK1126859T3 (da) Blodleukocyt-aferese til behandling af HIV
DE60131495D1 (de) Verfahren zur Herstellung von Composite-Membranen aus Perfluoropolymeren zur Gastrennung
DE60111747D1 (de) Verfahren zur herstellung von infektiösen reoviren
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
MXPA05005203A (es) Vacuna contra vhc.
ATE236999T1 (de) Verfahren zur reinigung bzw. isolierung viraler nukleinsäuren
ATE361334T1 (de) Verfahren zur herstellung von hochreinem polycarbonat
ATE480551T1 (de) Trennung von plasmakomponenten
DE50115263D1 (de) Verfahren zur gewinnung von reinem n-vinylpyrrolidon
DE69330238D1 (de) Verfahren zur Herstellung des Ectoproteins des Hepatitis-C-Virus
WO2001097824A3 (de) Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae
WO2003053332A3 (en) Composition and method for treating viral infection
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
WO2004058807A3 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
DE59610629D1 (de) Immunogenes konstrukt, verfahren zu dessen herstellung und verwendung als vakzine
WO2002087600A8 (de) Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch hepatitis b-viren
DE60118397D1 (de) Komplex aus den teilen des hepatitis c virus und lipoprotein geringer dichte, verfahren zu seiner herstellung und anwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1230347

Country of ref document: EP